- Home
- BBBY vs VOR Comparison
BBBY vs VOR Comparison
Compare BBBY & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBBY | VOR |
|---|---|---|
| Founded | 1971 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.5M | 562.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BBBY | VOR |
|---|---|---|
| Price | $4.52 | $17.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $7.67 | ★ $44.78 |
| AVG Volume (30 Days) | ★ 1.4M | 753.8K |
| Earning Date | 04-27-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.35 | N/A |
| Revenue Next Year | $7.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.31 | $0.13 |
| 52 Week High | $12.65 | $49.95 |
Technical Indicators
Market Signals| Indicator | BBBY | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 67.01 |
| Support Level | N/A | $11.38 |
| Resistance Level | $6.72 | $18.60 |
| Average True Range (ATR) | 0.22 | 1.21 |
| MACD | -0.01 | 0.30 |
| Stochastic Oscillator | 31.01 | 94.75 |
Price Performance
Historical ComparisonAbout BBBY Bed Bath & Beyond Inc.
Bed Bath & Beyond Inc is an ecommerce-focused retailer with an affinity model that owns or has ownership interests in various retail brands, offering a comprehensive array of products and services that enable its customers to enhance everyday life through quality, style, and value. The Company currently owns Bed Bath & Beyond, Overstock, buybuy BABY, and other related brands and websites as well as a blockchain asset portfolio.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.